New drug combo aims to tame deadly fat levels in the blood
NCT ID NCT07308392
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests two experimental injections, HRS-7249 and SHR-1918, in 108 adults with severely high triglycerides who are at high risk of acute pancreatitis. The study aims to see if these drugs can safely lower fat levels in the blood and reduce the chance of a pancreatitis attack. Participants are randomly assigned to receive either the drugs or a placebo, and researchers will track changes in triglyceride levels and pancreatitis events over nearly a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-7249 and SHR-1918 injections
- What this could lead to
- If successful, this could provide a new treatment option to lower dangerously high triglycerides and reduce the risk of acute pancreatitis.
- What could go wrong
- This is an early Phase 2 trial with only 108 participants, so results may not confirm effectiveness or safety. The drugs are experimental and may cause side effects or fail to outperform placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE HYPERTRIGLYCERIDEMIA WITH A HIGH RISK OF ACUTE PANCREATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital)
RECRUITINGNanjing, Jiangsu, 210029, China